June 14, 2023 | Wellness, Alzheimer’s Disease
Dr. Richard Pither, CEO of Cytox
This webinar will discuss Sampled's Alzheimer's Risk Test. A new non-invasive test that can assess an individual's genetic risk of cognitive decline due to Alzheimer’s disease. ART is now available on the Evexia Diagnostics platform, so can be conveniently ordered online. Topics will include: "How does ART work?" and "Is the Alzheimer’s Risk Test the same as APOE testing?". Speaker Biography: Dr. Richard Pither is CEO of Cytox, a company focusing on the development of products that enable an individual’s genetic risk assessment for Alzheimer’s disease to be determined. Richard was instrumental in developing genoSCORE™, the core technology used by Sampled to develop the Alzheimer’s Risk Test, now available to US clinicians. Richard also works with global pharmaceutical companies on the use of genoSCORE in clinical trial recruitment. Following academic training at Bristol University in the UK and Harvard Medical School, Richard has been involved in the diagnostic and therapeutic industry for more than thirty years including senior R&D roles at GE Healthcare (Medical Diagnostics) and UCB-Celltech.
Dr. Richard Pither is CEO of Cytox, a company focusing on the development of products that enable an individual’s genetic risk assessment for Alzheimer’s disease to be determined. Richard was instrumental in developing genoSCORE™, the core technology used by Sampled to develop the Alzheimer’s Risk Test, now available to US clinicians. Richard also works with global pharmaceutical companies on the use of genoSCORE in clinical trial recruitment. Following academic training at Bristol University in the UK and Harvard Medical School, Richard has been involved in the diagnostic and therapeutic industry for more than thirty years including senior R&D roles at GE Healthcare (Medical Diagnostics) and UCB-Celltech.